Clinical Trial
Comparative Study
English Abstract
Journal Article
Randomized Controlled Trial
Add like
Add dislike
Add to saved papers

[Sulfentanil citrate. Administration of intramuscular injections in conscious man (author's transl)].

In the case of a conscious man suffering from a painful injury in the facial and trigeminal nerves, the administration of intra-muscular injections of increasing doses of morphine and sulfentanil provokes constant analgesia in direct proportion to the administered dose. The admitted dosages for each product are as follows. M = 0,100, 0,150, 0,200 mg/kg S = 0,00015, 0,0003, 0,0006 mg/kg. Sulfentanil is a highly active analgesic whose activity is about 333 times greater than that of morphine and 13 times greater than that of fentanyl. In the case of each of the 3 products, the point at which analgesia becomes clinically discernable is the same. Optimum intensity of action of the analgesia is arrived at in all 3 cases within a period of 60 to 90 minutes. The higher the dose administered, the longer sulfentanil can be expected to work. Although effective for a shorter period of time than morphine and fentanyl sulfentanil effectiveness is too great for it to be considered a short-acting analgesic.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app